EA201290938A1 - Конъюгированный фактор свертывания крови viii - Google Patents

Конъюгированный фактор свертывания крови viii

Info

Publication number
EA201290938A1
EA201290938A1 EA201290938A EA201290938A EA201290938A1 EA 201290938 A1 EA201290938 A1 EA 201290938A1 EA 201290938 A EA201290938 A EA 201290938A EA 201290938 A EA201290938 A EA 201290938A EA 201290938 A1 EA201290938 A1 EA 201290938A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood volume
fviii
conjugated
volume viii
conjugated factor
Prior art date
Application number
EA201290938A
Other languages
English (en)
Russian (ru)
Inventor
Вильям Генри
Original Assignee
Кантаб Биофармасьютикалз Пэтентс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290938(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кантаб Биофармасьютикалз Пэтентс Лимитед filed Critical Кантаб Биофармасьютикалз Пэтентс Лимитед
Publication of EA201290938A1 publication Critical patent/EA201290938A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201290938A 2010-04-30 2011-04-28 Конъюгированный фактор свертывания крови viii EA201290938A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii

Publications (1)

Publication Number Publication Date
EA201290938A1 true EA201290938A1 (ru) 2013-04-30

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290938A EA201290938A1 (ru) 2010-04-30 2011-04-28 Конъюгированный фактор свертывания крови viii

Country Status (26)

Country Link
US (1) US20130150302A1 (https=)
EP (1) EP2563402A1 (https=)
JP (1) JP5870088B2 (https=)
KR (1) KR20130055619A (https=)
CN (1) CN102939108A (https=)
AP (1) AP2012006575A0 (https=)
AU (1) AU2011247147B2 (https=)
BR (1) BR112012027590A2 (https=)
CA (1) CA2797058A1 (https=)
CL (1) CL2012003039A1 (https=)
CO (1) CO6660443A2 (https=)
CR (1) CR20120579A (https=)
EA (1) EA201290938A1 (https=)
EC (1) ECSP12012314A (https=)
GB (2) GB201007357D0 (https=)
IL (1) IL222566A (https=)
MX (1) MX2012012683A (https=)
MY (1) MY160922A (https=)
NI (1) NI201200160A (https=)
NZ (1) NZ603939A (https=)
PE (1) PE20130254A1 (https=)
PH (1) PH12012502150A1 (https=)
RU (1) RU2012144555A (https=)
SG (1) SG184906A1 (https=)
WO (1) WO2011135307A1 (https=)
ZA (1) ZA201208989B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
MX2020012103A (es) 2018-05-18 2021-01-29 Zhengzhou Gensciences Inc Proteina de fusion fviii mejorada y uso de la misma.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
CL2012003039A1 (es) 2014-01-24
MY160922A (en) 2017-03-31
JP5870088B2 (ja) 2016-02-24
HK1173946A1 (en) 2013-05-31
IL222566A0 (en) 2012-12-31
RU2012144555A (ru) 2014-06-10
IL222566A (en) 2017-12-31
ZA201208989B (en) 2014-02-26
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB201220667D0 (en) 2013-01-02
AP2012006575A0 (en) 2012-12-31
ECSP12012314A (es) 2013-05-31
SG184906A1 (en) 2012-11-29
PE20130254A1 (es) 2013-03-16
GB201007357D0 (en) 2010-06-16
GB2492935B (en) 2014-04-30
CR20120579A (es) 2013-04-25
BR112012027590A2 (pt) 2016-08-09
PH12012502150A1 (en) 2013-02-04
NZ603939A (en) 2013-08-30
AU2011247147A1 (en) 2013-01-10
CN102939108A (zh) 2013-02-20
GB2492935A (en) 2013-01-16
JP2013525414A (ja) 2013-06-20
GB2492935B8 (en) 2014-10-29
CO6660443A2 (es) 2013-04-30
WO2011135307A1 (en) 2011-11-03
EP2563402A1 (en) 2013-03-06
MX2012012683A (es) 2013-04-03
NI201200160A (es) 2013-04-19
KR20130055619A (ko) 2013-05-28
AU2011247147B2 (en) 2014-09-18
CA2797058A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
EA201290938A1 (ru) Конъюгированный фактор свертывания крови viii
EA201290941A1 (ru) КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
CY1119684T1 (el) Αντι-ιικες ενωσεις
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1119725T1 (el) Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
MX395271B (es) Composicion farmaceutica.
EA201190297A1 (ru) Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их получения и применения
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции
TR200900882A2 (tr) Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
TR201007106A1 (tr) Sefpodoksim proksetil formülasyonları.
CY1117968T1 (el) Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
FI20145955L (fi) Antipatogeenisia koostumuksia